GeneNova, a new innovation milieu with the goal to develop novel production methods for adeno-associated virus based gene therapies, has just been launched.
The five-year project is coordinated by KTH Royal Institute of Technology and financed by Sweden’s innovation agency, Vinnova, together with the industrial and academia partners AlfaLaval, Astra Zeneca, Biotage, CombiGene, KTH Royal Institute of Technology, Karolinska Institute, Vironova, Uppsala University, and Ziccum.
Vironova will contribute with transmission electron microscopy imaging and analysis expertise, and lead the high through-put microscopy and next generation sequencing work package, aiming to develop novel analysis methods of gene therapy vectors and cargo, as well as monitor and optimize the production process.
"We are proud and honored to be part of this innovative and disruptive project and to contribute with our pieces of the 'gene therapy technology puzzle'", says Vironova’s CEO Mohammed Homman.
Read more on the GeneNova project website
27June, 2022
